Outcome of Board Meeting

Date: 26 October 2026 To To BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers Exchange Plaza Dalal Street Bandra Kurla Complex, Bandra (E) Mumbai- 400001 Mumbai-400051 Security Code: 540596 Symbol: ERIS SUBJECT: OUTCOME OF THE BOARD MEETING HELD TODAY, i.e., October 26, 2026 Dear Sir/Madam, Pursuant to Regulation 30 read with Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, (“LODR”) we hereby inform you that the Board of Directors of the Company, in their meeting held today, i.e., October 26, 2026, inter alia, duly approved and took on record Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended September 30, 2026. In this regard, the following documents are enclosed: • A copy of the said financial results along with Limited review report pursuant to Regulation 33 and Regulation 52 of the SEBI Listing Regulations. The limited review reports are submitted with unmodified opinion(s) (free from any qualifications). • Details as per Regulation 52(4) of SEBI Listing Regulations. The meeting of the Board of Directors commenced at 11:00 A.M. and concluded at 01:40 P.M. This is for your information and record. Thanking You, For Eris Lifesciences Limited Milind Talegaonkar Company Secretary & Compliance Officer Membership No: A26493 Walker Chandiok & Co LLP Block No. D/15th Floor, Cabin No. A8 to A10 S.G Highway, Sarkhej Road, Ahmedabad-380015 Gujarat, India Year to Date Results of the Company pursuant to the Regulation 33 and Regulation 52 read with Regulation 63 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) To the Board of Directors of Eris Lifesciences Limited 1. We have reviewed the accompanying statement of unaudited consolidated financial results of Eris Lifesciences Limited (refer Annexure 1 for the list of subsidiaries and joint venture included in the Statement) for the quarter ended 30 September 2026 and the consolidated year to date results for the period 1 April 2026 to 30 September 2026 being submitted by the Holding Company pursuant to the requirements of Regulation 33 and Regulation 52 read with Regulation 63 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) . the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standar principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 and Regulation 52 read with Regulation 63 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. Chartered Accountants Walker Chandiok & Co LLP is registered with limited liability with identification number AAC- Offices in Ahmedabad, Bengaluru, Chandigarh, Chennai, Dehradun, Goa, Gurugram, Hyderabad, Indore, Kochi, Kolkata, 2085 and has its registered office at L-41, Mumbai, New Delhi, Noida and Pune Connaught Circus, Outer Circle, New Delhi, 110001, India We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the Listing Regulations, to the extent applicable. 4. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 and Regulation 52 read with Regulation 63of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement. 5. We did not review the interim financial results of 5 subsidiaries included in the Statement, whose 1,474.07 Crores as at 30 September 2026, and total 163.96 Crores 275.14 Crores, total net profit 30.66 Crores 42.44 Crores, 30.07 Crores 41.79 Crores for the quarter and six-monthperiod ended on 30 September 2026, respectively, and net cash inflows of 7.16Croresfor the period ended 30 September 2026, as considered in the Statement. The Statement also includes the 0.90Crores 1.30Croresand total comprehensive loss 0.90Crores 1.30Croresfor the quarter and six-monthperiod ended on 30 September 2026, respectively, as considered in the Statement, in respect of one joint venture, whose interim financial results have not been reviewed by us. These interim financial results have been reviewed by other auditors whose review reports have been furnished to us by the management, and our conclusion in so far as it relates to the amounts and disclosures included in respect of these subsidiaries and joint venture is based solely on the review reports of such other auditors and the procedures performed by us as stated in paragraph 3 above. Our conclusion is not modified in respect ofthese matter with respect to our reliance on the work done by and the reports of the other auditors. ForWalker Chandiok & Co LLP Chartered Accountants Ashish Gupta Partner Membership No.: 504662 UDIN: 26504662LAQQUU4575 Place: New Delhi Date: 26 October 2026 Chartered Accountants Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 and Regulation 52 read with Regulation 63 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) List of entities included in the Statement Holding Company Sr. No. Name of entity 1 Eris Lifesciences Limited Subsidiaries Sr. No. Name of entities 1 Eris Therapeutics Limited 2 Eris Oaknet Healthcare Private Limited (Step-down subsidiary) 3 Eris Healthcare Private Limited 4 Eris M. J. Biopharm Private Limited 5 Eris Pharmaceuticals Limited 6 Eris Bionxt Private Limited 7 Swiss Parenterals Limited Joint venture Sr. No. Name of entity 1 Levim Lifetech Private Limited Chartered Accountants Eris 2013 Eris Lifesciences Limited EY Entrepreneur FROST & SULLIVAN Business today/YES bank of the year-2013 Best Practices-2013 Excellence Awards-2013 Statement of Unaudited Consolidated Financial results for the quarter and half year ended September 30, 2026 Rs in Crore except per share data) For quarter ended For half year ended For year ended Sr. September 30, June 30, 2026 September 30, September 30, September 30, Particulars March 31, 2026 No. 2026 (Unaudited) 2025 2026 2025 (Audited) (Unaudited) (Unaudited) (Unaudited) (Unaudited) 1 Income Revenue from operations Sale of products 889.50 869.03 790.15 1,758.53 1,561.71 3,114.89 Other operating income 2.87 4.22 2.26 7.09 3.70 14.53 Total Revenue from operations 892.37 873.25 792.41 1,765.62 1,565.41 3,129.42 Other income 3.20 2.39 2.81 5.59 5.50 7.75 Total income 895.57 875.64 795.22 1,771.21 1,570.91 3,137.17 2 Expenses Cost of materials consumed 107.86 94.27 82.58 202.13 152.68 326.65 Purchase of stock-in-trade 167.72 131.12 146.09 298.84 250.35 490.56 Changes in inventories of finishe [Showing first 8,000 characters — download PDF for full document]